Authors

Latest:

Dr Zackon on Next Steps for Evaluating the Real-World Use of Bispecific Antibodies in R/R Myeloma

Ira Zackon, MD, discusses the real-world use of bispecific antibodies for patients with R/R multiple myeloma in the community oncology setting.

Saurabh Dahiya, MD, FACP

Saurabh Dahiya, MD, FACP, is an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Latest:

Dr Dahiya on the Unique Mechanism of Action of KITE-363 in LBCL

Saurabh Dahiya, MD, FACP, discusses the unique mechanism of action of the CD19/CD20–targeting CAR T-cell therapy in relapsed/refractory LBCL.

Matthew Gavidia

Latest:

US Biosimilar Portfolio Hits 10-Year Mark in Growth Mode

Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.

Mary Katherine Montes de Oca, MD

Latest:

Dr Montes de Oca on the Use of Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancers

Mary Katherine Montes de Oca, MD, discusses the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in gynecologic cancers.

Igor Astsaturov, MD, PhD

Latest:

Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic Cancer

Although a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.

Samer Al Hadidi, MD, MS

Latest:

BCMA Bispecifics in the Clinic: Data, Toxicities, and Real-World Experience

Panelists discuss how dual-targeting bispecific therapies, exemplified by JNJ-78934804 (targeting BCMA and GPRC5D), show early potential to redefine treatment paradigms in heavily pretreated multiple myeloma, with impressive response rates and manageable safety profiles.

Bhuvana Ramkumar, MD

Latest:

The Future of Molecular Testing in NSCLC

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Michael C. Haffner, MD, PhD

Deborah L. Toppmeyer, MD

Latest:

Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast Cancer

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

Alexey Danilov, MD, PhD, City of Hope

Latest:

Dr Danilov on the Current and Potential Use of Pirtobrutinib in CLL

Alexey Danilov, MD, PhD, discusses the utility of pirtobrutinib in patients with chronic lymphocytic leukemia.

Adrian González-González

Latest:

Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.

Riad Salem, MD, Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Latest:

Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres

Riad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.

Midhun Malla, MD

Midhun Malla, MD of University of Alabama at Birmingham.

Latest:

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

Michael Shafique, MD

Latest:

Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Susan Marie Lang, MD

Latest:

Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian Cancer

Susan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.

Iris Y. Sheng, MD

Latest:

Struggling With COVID-19 on the Cancer Floor

For the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.

Rebecca Silbermann, MD, MMS

Latest:

Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory Myeloma

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Malcolm Mattes, MD

Latest:

Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCC

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

Margarita Majem

Latest:

Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLC

Margarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.

Raza Hoda, MD, FASCP

Latest:

Dr Hoda on Characterizing HR–Positive, HER2-Low, -Ultralow, and -Null Metastatic Breast Cancer

Raza Hoda, MD, FASCP, discusses characterizing hormone receptor–positive, HER2-low, -ultralow, and -null breast carcinoma in the metastatic setting.